New dialysis fluid tested against standard in small study
NCT ID NCT07621627
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how well a new dialysis solution works compared to the usual one in people with kidney failure who are on peritoneal dialysis. Seven stable patients each tried both solutions during a single 4-hour session. The goal was to measure fluid removal and changes in blood acid levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
7 people
The number who actually took part.
- Started
-
Sep 1997
- Finished
-
Nov 1997
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * patient treated with peritoneal dialysis in a clinically stable condition Exclusion Criteria: * none
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic renal failure (CRF) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research unit, renal medicine
Stockholm, S-141 86, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.